Latest | F'cast | |
---|---|---|
Div Yield | 1.2% | 0.0% |
Div Cover | 1.6 | n/a |
Op Mrgn | 15.2% | n/a |
ROCE | 46.6% |
Latest | F'cast | |
---|---|---|
P/E | 51.4 | n/a |
PEG | 8.2 | n/a |
Pr/Revenue | 4.9 | n/a |
Pr/Book | 7.4 |
Latest | F'cast | |
---|---|---|
Revenue | 13.6% | n/a |
PBT | 13.5% | n/a |
EPS | 6.3% | n/a |
DPS | 5.0% | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-20 | 538.40 | 66.70 | 56.40p | 39.0 | n/a | -12% | 30.00p | 1.4% |
30-Sep-21 | 787.40 | 96.60 | 85.20p | 33.4 | 0.7 | +51% | 42.60p | 1.5% |
30-Sep-22 | 1,012.80 | 129.50 | 107.50p | 21.6 | 0.8 | +26% | 53.80p | 2.3% |
30-Sep-23 | 1,200.30 | 155.60 | 90.80p | 33.1 | n/a | -16% | 56.50p | 1.9% |
30-Sep-24 | 1,363.40 | 176.60 | 96.50p | 45.9 | 7.7 | +6% | 59.30p | 1.3% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Holding(s) in Company | 20-Jun-2025 | 09:50 | RNS |
Holding(s) in Company | 09-Jun-2025 | 12:50 | RNS |
Holding(s) in Company | 28-May-2025 | 09:27 | RNS |
Drug shares on a high | 19-Nov-2006 | Scotland on Sunday |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 4,956.00p |
Change Today | 80.00p |
% Change | 1.64 % |
52 Week High | 4,960.00 |
52 Week Low | 3,624.00 |
Volume | 211,141 |
Shares Issued | 134.18m |
Market Cap | £6,650m |
Beta | 0.01 |
RiskGrade | 165 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 29-May-25 | 16-Jan-25 |
Paid | 13-Jun-25 | 31-Jan-25 |
Amount | 18.20p | 42.00p |
Time | Volume / Share Price |
16:37 | 15,476 @ 4,956.00p |
16:35 | 1,107 @ 4,956.00p |
16:35 | 90 @ 4,956.00p |
16:35 | 90,321 @ 4,956.00p |
16:35 | 258 @ 4,956.00p |
You are here: research